Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel blocks blood flow to tumors and stops bleeding

NCT ID NCT06170619

Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well a gel-like material called Obsidio works to block blood vessels in people with hypervascular tumors or bleeding. 125 adults were treated, and researchers checked if the vessels were successfully blocked and if there were any serious side effects within 30 days. The goal was to confirm the device is safe and effective in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Obsidio Conformable Embolic (a gel-like material injected into blood vessels to block blood flow)
What this could lead to
If successful, this registry confirms that Obsidio is a safe and effective option for blocking blood vessels to control bleeding or shrink tumors.
What could go wrong
This is a completed registry with 125 participants, so results are available but may not apply to all patients. Risks include unintended blockage of other vessels or injury to the target organ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

125 people

The number who actually took part.

Started

Jun 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who will undergo or have undergone embolization with Obsidio™ Conformable Embolic

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is ≥ 18 years of age * Signed informed consent\* * Patient is to undergo or has undergone embolization with Obsidio™ Conformable Embolic * Patient is willing and able to comply with protocol requirements, including all procedures, clinical evaluations, and follow-up visits \*Patients being treated for control of bleeding/hemorrhage who are unable to consent prior to their procedure, can be enrolled if the informed consent is provided and signed within 72 hours of the index procedure Exclusion Criteria: * Patient has a life expectancy \< 30 days * Contraindications to receiving Obsidio™ Conformable Embolic per the Instructions For Use (IFU) * Embolization for uterine fibroids, prostate artery, genicular artery, ovarian vein, spermatic vein, pulmonary arteriovenous malformations, bronchial artery, asymptomatic benign tumors, portal vein, varices, lymphatic/thoracic duct, nonvascular channel (e.g. ureter, intestinal fistula) * Patients with more than 2 discrete lesions, defined as a treatment area that may be fed by one or more vessels

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding Hemorrhage Hypervascular tumors

Contacts and locations

Locations

  • Albany Medical Center

    Albany, New York, 12208, United States

  • Barnes Jewish Hosital

    St Louis, Missouri, 63110, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Christiana Hospital

    Newark, Delaware, 19718, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Hospital

    Phoenix, Arizona, 85054, United States

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • Mercy Hospital

    Coon Rapids, Minnesota, 55433, United States

  • Mount Sinai Medical Center

    New York, New York, 10029, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California, 90095, United States

  • St. Joseph's Medical Center

    Stockton, California, 95204, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University Hospital

    Newark, New Jersey, 07103, United States

  • University of Chicago Hospital

    Chicago, Illinois, 60637, United States

  • University of Kansas Hospital

    Kansas City, Kansas, 66160, United States

  • University of North Carolina Hospital

    Chapel Hill, North Carolina, 27599, United States

  • University of Texas Houston Health Science Center

    Houston, Texas, 77030, United States

  • University of Washington Medical Center

    Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.